144 related articles for article (PubMed ID: 36584232)
1. Hiding Payload Inside the IgG Fc Cavity Significantly Enhances the Therapeutic Index of Antibody-Drug Conjugates.
Shi W; Zhang J; Liu L; Li W; Liu Z; Ren A; Wang J; Tang C; Yang Y; Xu D; Huang Q; Wang Y; Luo C; Huang W; Tang F
J Med Chem; 2023 Jan; 66(1):1011-1026. PubMed ID: 36584232
[TBL] [Abstract][Full Text] [Related]
2. Homogeneous Antibody-Drug Conjugates via Glycoengineering.
Tang F; Shi W; Huang W
Methods Mol Biol; 2019; 2033():221-238. PubMed ID: 31332757
[TBL] [Abstract][Full Text] [Related]
3. One-step synthesis of site-specific antibody-drug conjugates by reprograming IgG glycoengineering with LacNAc-based substrates.
Shi W; Li W; Zhang J; Li T; Song Y; Zeng Y; Dong Q; Lin Z; Gong L; Fan S; Tang F; Huang W
Acta Pharm Sin B; 2022 May; 12(5):2417-2428. PubMed ID: 35646546
[TBL] [Abstract][Full Text] [Related]
4. The Chemical Design and Synthesis of Linkers Used in Antibody Drug Conjugates.
Frigerio M; Kyle AF
Curr Top Med Chem; 2017; 17(32):3393-3424. PubMed ID: 29357801
[TBL] [Abstract][Full Text] [Related]
5. Antibody-Drug Conjugates (ADCs) Derived from Interchain Cysteine Cross-Linking Demonstrate Improved Homogeneity and Other Pharmacological Properties over Conventional Heterogeneous ADCs.
Behrens CR; Ha EH; Chinn LL; Bowers S; Probst G; Fitch-Bruhns M; Monteon J; Valdiosera A; Bermudez A; Liao-Chan S; Wong T; Melnick J; Theunissen JW; Flory MR; Houser D; Venstrom K; Levashova Z; Sauer P; Migone TS; van der Horst EH; Halcomb RL; Jackson DY
Mol Pharm; 2015 Nov; 12(11):3986-98. PubMed ID: 26393951
[TBL] [Abstract][Full Text] [Related]
6. Synthesis, characterization, and targeted chemotherapy of SCT200-linker-monomethyl auristatin E conjugates.
Hu X; Jiang H; Bai W; Liu X; Miao Q; Wang L; Jin J; Cui A; Liu R; Li Z
Eur J Med Chem; 2021 Apr; 216():113297. PubMed ID: 33677351
[TBL] [Abstract][Full Text] [Related]
7. Polyethylene glycol-based linkers as hydrophilicity reservoir for antibody-drug conjugates.
Tedeschini T; Campara B; Grigoletto A; Bellini M; Salvalaio M; Matsuno Y; Suzuki A; Yoshioka H; Pasut G
J Control Release; 2021 Sep; 337():431-447. PubMed ID: 34329685
[TBL] [Abstract][Full Text] [Related]
8. Chemical Site-Specific Conjugation Platform to Improve the Pharmacokinetics and Therapeutic Index of Antibody-Drug Conjugates.
Matsuda Y; Seki T; Yamada K; Ooba Y; Takahashi K; Fujii T; Kawaguchi S; Narita T; Nakayama A; Kitahara Y; Mendelsohn BA; Okuzumi T
Mol Pharm; 2021 Nov; 18(11):4058-4066. PubMed ID: 34579528
[TBL] [Abstract][Full Text] [Related]
9. [Novel Chemical Linkers for Next-generation Antibody-drug Conjugates(ADCs)].
Tsuchikama K
Yakugaku Zasshi; 2019; 139(2):209-219. PubMed ID: 30713230
[TBL] [Abstract][Full Text] [Related]
10. ez-ADiCon: A novel glyco-remodeling based strategy that enables preparation of homogenous antibody-drug conjugates via one-step enzymatic transglycosylation with payload-preloaded bi-antennary glycan complexes.
Chon H; Kanamori S; Hibino K; Nagahara T; Suzuki T; Ohara K; Narumi H
Bioorg Med Chem Lett; 2023 Jan; 80():129117. PubMed ID: 36584791
[TBL] [Abstract][Full Text] [Related]
11. Antibody-drug conjugates: recent advances in conjugation and linker chemistries.
Tsuchikama K; An Z
Protein Cell; 2018 Jan; 9(1):33-46. PubMed ID: 27743348
[TBL] [Abstract][Full Text] [Related]
12. Antibody Conjugations via Glycosyl Remodeling.
Toftevall H; Nyhlén H; Olsson F; Sjögren J
Methods Mol Biol; 2020; 2078():131-145. PubMed ID: 31643054
[TBL] [Abstract][Full Text] [Related]
13. Modulation of drug-linker design to enhance in vivo potency of homogeneous antibody-drug conjugates.
Pabst M; McDowell W; Manin A; Kyle A; Camper N; De Juan E; Parekh V; Rudge F; Makwana H; Kantner T; Parekh H; Michelet A; Sheng X; Popa G; Tucker C; Khayrzad F; Pollard D; Kozakowska K; Resende R; Jenkins A; Simoes F; Morris D; Williams P; Badescu G; Baker MP; Bird M; Frigerio M; Godwin A
J Control Release; 2017 May; 253():160-164. PubMed ID: 28257988
[TBL] [Abstract][Full Text] [Related]
14. Novel linkers and connections for antibody-drug conjugates to treat cancer and infectious disease.
Pillow TH
Pharm Pat Anal; 2017 Jan; 6(1):25-33. PubMed ID: 28155578
[TBL] [Abstract][Full Text] [Related]
15. Tubulin Inhibitor-Based Antibody-Drug Conjugates for Cancer Therapy.
Chen H; Lin Z; Arnst KE; Miller DD; Li W
Molecules; 2017 Aug; 22(8):. PubMed ID: 28763044
[TBL] [Abstract][Full Text] [Related]
16. Optimization of a PEGylated Glucuronide-Monomethylauristatin E Linker for Antibody-Drug Conjugates.
Burke PJ; Hamilton JZ; Jeffrey SC; Hunter JH; Doronina SO; Okeley NM; Miyamoto JB; Anderson ME; Stone IJ; Ulrich ML; Simmons JK; McKinney EE; Senter PD; Lyon RP
Mol Cancer Ther; 2017 Jan; 16(1):116-123. PubMed ID: 28062707
[TBL] [Abstract][Full Text] [Related]
17. The Properties of Cysteine-Conjugated Antibody-Drug Conjugates Are Impacted by the IgG Subclass.
Datta-Mannan A; Choi H; Stokell D; Tang J; Murphy A; Wrobleski A; Feng Y
AAPS J; 2018 Sep; 20(6):103. PubMed ID: 30255287
[TBL] [Abstract][Full Text] [Related]
18. Aldehyde tag coupled with HIPS chemistry enables the production of ADCs conjugated site-specifically to different antibody regions with distinct in vivo efficacy and PK outcomes.
Drake PM; Albers AE; Baker J; Banas S; Barfield RM; Bhat AS; de Hart GW; Garofalo AW; Holder P; Jones LC; Kudirka R; McFarland J; Zmolek W; Rabuka D
Bioconjug Chem; 2014 Jul; 25(7):1331-41. PubMed ID: 24924618
[TBL] [Abstract][Full Text] [Related]
19. Synthesis and Evaluation of Three Azide-Modified Disaccharide Oxazolines as Enzyme Substrates for Single-Step Fc Glycan-Mediated Antibody-Drug Conjugation.
Zhang X; Ou C; Liu H; Wang LX
Bioconjug Chem; 2022 Jun; 33(6):1179-1191. PubMed ID: 35543724
[TBL] [Abstract][Full Text] [Related]
20. Practical approaches for overcoming challenges in heightened characterization of antibody-drug conjugates with new methodologies and ultrahigh-resolution mass spectrometry.
Friese OV; Smith JN; Brown PW; Rouse JC
MAbs; 2018 Apr; 10(3):335-345. PubMed ID: 29393747
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
